NEWS 9
ausdoc. com. au 18 JULY 2025
NEWS 9
Cancer Council slapped over sloppy SPF
Jamie Thannoo SIXTEEN of 20 sunscreens labelled as |
UV rays that reaches the skin when sunscreen is applied at 2mg / sq cm. |
For Choice’ s tests, it applied sunscreen to part of a person’ s body and |
|
testing by an independent international laboratory,” the charity said in |
sun protection factor 50 offer signifi- |
SPF 50 indicates that only 2 % of |
then used a sun simulator to apply |
a statement. |
cantly less protection, including Can- |
UV radiation reaches the skin. |
incrementally increasing doses of |
“ All necessary actions to any find- |
cer Council products, says consumer |
While the percentage difference |
light to the test area and non-sun- |
ings will be implemented.” |
advocacy group Choice. |
between SPF 50 and SPF 30 is small— |
screen areas, comparing how quickly |
Other companies given SPF in |
Choice says the dismal results— |
2 % of radiation reaching the skin ver- |
they turned red. |
the 20s-40s in Choice’ s tests told the |
including one sunscreen it said had |
sus 3.3 %— it also affects how quickly |
Kids Sunscreen SPF 50 + was the |
advocacy group that their products |
a sun protection factor( SPF) of 4— |
damage occurs. |
only one of four Cancer Council sun- |
did meet standards but that they |
mean the TGA should conduct its own |
If it normally takes five minutes |
screens that passed the test. |
would commission independent tests |
testing and stop relying on company- |
for UV radiation to turn skin red, |
“ Noting the test results published |
to verify. |
submitted reports from credentialled |
with SPF 50 sunscreen, it should take |
by Choice and out of an abundance |
The TGA said it was investigat- |
laboratories. |
250 minutes, and with SPF 30, 180 |
of caution, we have submitted the |
ing the findings and would act if |
SPF is a measure of the fraction of |
minutes. |
four referenced products for further |
necessary. |
Avoid‘ dollmaker’ ads: AHPRA
Antony Scholefield NEW AHPRA guidelines warn cosmetic doctors to stop advertising with terms such as“ doll-maker”,“ sculptor”,“ artist” or“ magic hands”.
Two new guidelines on non-surgical cosmetic procedures will take effect in September: one regarding advertising and one setting standards for all health practitioners similar to those already in place for doctors.
The advertising guidelines, which apply to“ higher-risk cosmetic procedures”— such as botox, dermal fillers or platelet-rich plasma injections— warn against“ pathologising normal appearance or encouraging cosmetic procedures to fix normal variations”.
Nomenclature that“ trivialises” procedures, such as dollmaker, is deemed bad practice. So are images of oiled bodies, women in lingerie or people striking poses“ suggestive of sexual positions … parting of legs, hands placed near genitals or positions that imply sexual readiness”.
Ads that mention individual doctors or nurses should include their AHPRA number, whether doctors have general or specialist registration and whether nurses are ENs or RNs, the guidelines add.
The second guidelines say RNs performing cosmetic procedures must have worked full-time in another area of nursing for at least a year since their first registration.
“ This is in recognition that RNs who perform non-surgical cosmetic procedures are required to undertake detailed assessment, planning and delegation of care; have complex anatomical and physiology knowledge; as well as decision-making relating to pharmacodynamics and pharmacokinetics.”
ENs can only work under RN supervision, not even under GP supervision. However, supervision can be indirect, with the RN offsite but“ readily available”.
RSV infections can occur all year round * 1,2
* Infections peak in the cooler months in temperate regions and after the rainy season in tropical regions in Australia. 1-3
Protection against RSV-LRTD starts with AREXVY †
†
AREXVY is indicated for active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus( RSV). Vaccines may not protect all recipients. 4
AREXVY has data on efficacy against RSV-LRTD over ~ 18 months in adults aged ≥60 years ‡ 5, 6
‡
Median follow-up of 17.8 months, or over two RSV seasons. 5, 6
SCAN OR VISIT GSKPRO. COM
TO LEARN MORE
Hypothetical patients for illustrative purposes only.
SCAN QR CODE to see full AREXVY
Product Information
Dosing and administration: AREXVY is administered as a single, reconstituted dose of 0.5 mL by intramuscular injection. The need for revaccination has not been established. Safety: Very common adverse events( ≥10 %) are headache, myalgia, arthralgia, injection site pain and fatigue. Common adverse events( ≥1 %) are injection site erythema, injection site swelling, fever, chills and rhinorrhoea( not a complete list; see full PI). 4
PBS Information: AREXVY is not listed on the PBS or the National Immunisation Program( NIP).
Please review Product Information before prescribing. Product Information can be accessed at www. gsk. com. au / arexvy ▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www. tga. gov. au / reportingproblems. RSV, respiratory syncytial virus; RSV-LRTD, RSV-related lower respiratory tract disease. References: 1. Di Giallonardo F et al. Viruses 2018; 10( 9): 476. 2. Paynter S et al. Aust N Z J Public Health 2015; 39( 1): 8 – 10. 3. Obando-Pacheco P et al. J Infect Dis 2018; 217( 9): 1356 – 64. 4. AREXVY Product Information. 5. Papi A et al. N Engl J Med 2023; 388( 7): 595 – 608. 6. Ison MG et al. Clin Infect Dis 2024; 78( 6): 1732 – 44. For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. © 2024 GSK group of companies or its licensor. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline Australia Pty Ltd, Melbourne, VIC. PM-AU-RSA-JRNA-240004. Date of approval: October 2024.